| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Date of Report (Date of earliest event reported): November 16, 2026 |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
NEW HAVEN, Conn., October 29, 2026/PRNewswire/ Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies... |
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. Excluded information ... |
| 10 Sep 2026 |
8-K: Other Events
Biohaven Ltd. (the “Company,” “we” or “our”) is providing updates to the BHV-7000 program. We refer you to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for a description of the BHV-7000 program. |
| 26 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain confidential information contained in this exhibit has been omitted by means of redacting a portion of the text and replacing it with [***], pursuant to Regulation S-K Item 601(b)(10) of the Securities Act of 1933, as amended. Ce... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
NEW HAVEN, Conn., August 10, 2026 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapi... |
| 07 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a director, effective August 6, 2026. Mr. Yetimoglu will serve in the class of directors whose term will expire at the C... |
| 09 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
NEW HAVEN, Conn., July 9, 2026 — Biohaven Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has... |
| 27 May 2026 |
8-K: Regulation FD Disclosure
© 2026 Biohaven, Ltd. All rights reserved. Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY May ... |
| 05 May 2026 |
8-K: Other Events
We have acted as counsel as to British Virgin Islands law to the Company in respect of the proposed issuance of up to US$350,000,000 in aggregate offering price of common shares in the Company with no par value (the "Shares") from time t... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
NEW HAVEN, Conn., May 4, 2026 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies t... |
| 04 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On April 28, 2026, Biohaven Ltd. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition
clinic with potential subcutaneous route of administration. Additionally, first-in-class FGFR3 directed ADC, BHV-1530, continues with dose escalation and no dose limiting toxicities to date. |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
© 2026 Biohaven, Ltd. All rights reserved. Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY Corp... |
| 07 Jan 2026 |
8-K: Other Events
On January 6, 2026, Biohaven Ltd. (the “Company”) agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share. The Company expects to receive $125 million in gross proceeds upon ... |
| 13 Nov 2025 |
8-K: Other Events
Biohaven Ltd., a British Virgin Islands (“BVI”) business company (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC and Goldman Sac... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
NEW HAVEN, Conn., November 10, 2025 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing thera... |
| 22 Aug 2025 |
8-K: Regulation FD Disclosure
Biohaven Ltd. (the “Company”) provided the following update with respect to its New Drug Application (“NDA”) for troriluzole for the treatment of adult patients with Spinocerebellar Ataxia (“SCA”). |
| 15 Aug 2025 |
8-K: Other Events
We have acted as counsel as to British Virgin Islands law to the Company in respect of the proposed resale of an aggregate of 3,588,688 common shares in the Company with no par value (the "Shares") issued on 25 June 2025 to the Selling S... |
Loading...